Health Condition 1: B354- Tinea corporis
Conditions
Interventions
Intervention1: luliconazole 1percent cream: topical application of luliconazole to systemic antifungal for glabrous tinea
Control Intervention1: Terbinafine tablet 250mg BD: Adding topical to systemic
Sponsors
Nil
Eligibility
Inclusion criteria
Inclusion criteria: Extent of disease involving less than 10 percentage of body surface area. Those with positive KOH at first assessment. Those who have not taken any systemic antifungal in preceeding 4weeks and any topical antifungal or topical steroid in preceeding 2weeks. willing to be part of trial.
Exclusion criteria
Exclusion criteria: Pregnant and lactating females. Those recieving systemic drugs with major pharmacokinetic interactions with Terbinafine. Patients with systemic comorbidities.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate cure rates with Luliconazole 1%cream and systemic antifungal drug, versus only systemic antifungal drug in patients of glabrous tinea.Timepoint: To evaluate cure rates with Luliconazole 1%cream and systemic antifungal drug, versus only systemic antifungal drug in patients of glabrous tinea. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate cost effectiveness of treatment of both groups. To evaluate the duration of treatment of both groups. To assess relapse rate after complete cure of both groups.Timepoint: | — |
Countries
India
Contacts
Public ContactDR SHARDA LONGANI
RML hospital
Outcome results
None listed